SG190449A1 - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients Download PDF

Info

Publication number
SG190449A1
SG190449A1 SG2013042403A SG2013042403A SG190449A1 SG 190449 A1 SG190449 A1 SG 190449A1 SG 2013042403 A SG2013042403 A SG 2013042403A SG 2013042403 A SG2013042403 A SG 2013042403A SG 190449 A1 SG190449 A1 SG 190449A1
Authority
SG
Singapore
Prior art keywords
improving
laquinimod
life
multiple sclerosis
functional status
Prior art date
Application number
SG2013042403A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG190449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of SG190449A1 publication Critical patent/SG190449A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG2013042403A 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients SG190449A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
SG190449A1 true SG190449A1 (en) 2013-07-31

Family

ID=46162796

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013042403A SG190449A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
SG10201509831XA SG10201509831XA (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201509831XA SG10201509831XA (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (enExample)
EP (1) EP2648732A4 (enExample)
JP (2) JP2013544887A (enExample)
KR (1) KR20130124518A (enExample)
CN (1) CN103260624B (enExample)
AU (2) AU2011338647A1 (enExample)
BR (1) BR112013014061A2 (enExample)
CA (1) CA2820586A1 (enExample)
CL (1) CL2013001602A1 (enExample)
EA (1) EA201390827A1 (enExample)
IL (1) IL250726A0 (enExample)
MX (1) MX2013006464A (enExample)
NZ (1) NZ611628A (enExample)
PE (1) PE20140872A1 (enExample)
PH (1) PH12013501193A1 (enExample)
SG (2) SG190449A1 (enExample)
UA (1) UA111959C2 (enExample)
WO (1) WO2012078591A1 (enExample)
ZA (1) ZA201304237B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201508623RA (en) * 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (en) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011109526A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
MX2012010066A (es) * 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014052933A1 (en) * 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014127139A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
KR20170005434A (ko) * 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
WO2016059571A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
CA3115269A1 (en) * 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
EP4003338A1 (en) * 2019-07-22 2022-06-01 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1797109T3 (en) * 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
DK2653873T3 (da) * 2007-02-08 2022-07-25 Biogen Ma Inc Sammensætninger og anvendelser til behandling af multipel sklerose
EP2442651B1 (en) * 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod

Also Published As

Publication number Publication date
ZA201304237B (en) 2014-08-27
MX2013006464A (es) 2013-07-29
PE20140872A1 (es) 2014-08-09
PH12013501193A1 (en) 2013-07-15
EP2648732A4 (en) 2014-04-30
AU2011338647A8 (en) 2013-09-05
US20120142730A1 (en) 2012-06-07
IL250726A0 (en) 2017-04-30
BR112013014061A2 (pt) 2016-09-13
NZ611628A (en) 2015-06-26
CA2820586A1 (en) 2012-06-14
AU2011338647A1 (en) 2013-07-04
UA111959C2 (uk) 2016-07-11
EP2648732A1 (en) 2013-10-16
SG10201509831XA (en) 2015-12-30
CL2013001602A1 (es) 2013-10-25
CN103260624A (zh) 2013-08-21
KR20130124518A (ko) 2013-11-14
JP2017095476A (ja) 2017-06-01
CN103260624B (zh) 2015-06-03
AU2017202055A1 (en) 2017-04-20
WO2012078591A8 (en) 2012-08-02
JP2013544887A (ja) 2013-12-19
EA201390827A1 (ru) 2013-12-30
WO2012078591A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
IL250726A0 (en) Use of lequinimod to reduce fatigue, improve function and improve quality of life in multiple sclerosis patients
IL252699A0 (en) Use of lequinimod to treat multiple sclerosis
ZA201403378B (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
GB2481911B (en) Hard face structure, body comprising same and method for making same
EP2686514B8 (en) Integral wear pad and method
PL2685994T3 (pl) Bakterie probiotyczne wykazujące aktywność przeciwutleniającą i ich zastosowanie
ZA201401217B (en) Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AP2014007805A0 (en) Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
EP2716669A4 (en) METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE
DK2750705T3 (en) Methods for effectively and rapidly desensitizing allergic patients
SG11201401949YA (en) Nadph oxidase 4 inhibitors and use thereof
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
GB0920258D0 (en) New medical agents and use thereof
IL232174A0 (en) Preparations containing a salt of a sodium channel inhibitor and their uses
SMT201700098T1 (it) Aclidinio per l'uso nel miglioramento della qualità del sonno in pazienti con malattie respiratorie
HUE044588T2 (hu) Fitoekdizonok elhízott és szarkopéniás emlõsök izomzat-minõségének javítására szolgáló alkalmazásra
HK1188950A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2781227A4 (en) ELEMENT FOR USE IN A TEXTILE GENERATION, MANUFACTURING METHOD AND INK
PL391898A1 (pl) Proteza do regeneracji nerwu obwodowego i sposób wytwarzania protezy do regeneracji nerwu obwodowego
HK1193751A (en) Aclidinium for use in improving the quality of sleep in respiratory patients
GB201216724D0 (en) Note pad and method of use thereof
EG27140A (en) Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
IL215573A0 (en) Scouring sponge with symbol of " meet" , " milk" and " parve"
TWM402465U (en) Mouse pad for use in wheelchair